Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2022-06-16 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
Regulatory Filings Classification · 95% confidence The document is a press release dated June 16, 2022, announcing a future webcast event scheduled for June 28, 2022, which will feature KOLs discussing clinical trial updates (NATiV3, LEGEND) and scientific abstracts from the EASL International Liver Congress™ 2022. This is an announcement about an upcoming event and presentation of scientific data, not the full financial report (10-K, IR) or the transcript of the event itself (CT). Since it is an announcement related to investor relations, scientific updates, and future events, it most closely aligns with an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the detailed scientific and clinical updates being highlighted for investors, 'Investor Presentation' (IP) is the most specific fit, as it details the content that will be presented, even though the actual presentation event is in the future. The document also mentions where the presentation document will be available ('Investors – Investor Presentations' section), reinforcing the IP classification.
2022-06-16 English
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
Regulatory Filings Classification · 95% confidence The document is titled "Inventiva annonce la présentation de trois abstracts scientifiques lors de l'EASL International Liver Congress™ 2022" and details scientific findings (abstracts) related to their drug lanifibranor that will be presented at a medical conference. This is a press release announcing scientific data presentation, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). It is an announcement about scientific progress and participation in an industry event. Since it is a press release announcing scientific data/updates, it fits best under the general category for regulatory/corporate announcements that aren't covered by more specific codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate press release announcing scientific updates, although 'Investor Presentation' (IP) might seem close, this document is an announcement *about* presentations, not the presentation itself. However, since it is a formal announcement of corporate news (scientific data presentation), and not a financial report, RNS is the best fit as a general corporate communication.
2022-06-09 French
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
Regulatory Filings Classification · 95% confidence The document is titled "Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022" and details abstracts selected for poster presentations at a medical conference. It is a formal announcement about scientific data dissemination, not a comprehensive financial report (like 10-K or IR), a management discussion (MDA), or a formal earnings release (ER). Since it is an announcement detailing scientific findings and presentations, it most closely aligns with a general corporate communication or regulatory filing that doesn't fit the other specific categories. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for corporate announcements that are not explicitly financial results, management changes, or shareholder actions, although 'Investor Presentation' (IP) is related to the content, the document itself is an announcement *about* presentations, not the presentation slides themselves. However, because it is a press release announcing scientific data dissemination, which is a common type of corporate communication, RNS is the most appropriate fallback if a more specific category like 'IP' (Investor Presentation) is reserved for the actual slide deck. Since this is a press release announcing scientific abstracts for a conference, RNS (Regulatory Filings/General Announcement) is the most suitable classification.
2022-06-09 English
Inventiva joins the Euronext Tech Leaders segment
Regulatory Filings Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (PRESS RELEASE) and announces that Inventiva has been selected for inclusion in the Euronext Tech Leaders segment. This is a general corporate announcement regarding a market/index inclusion, not a detailed financial report (like 10-K or IR), an earnings release (ER), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI). Since it is a press release announcing a corporate event that doesn't fit the more specific categories (like ER, DIV, CAP, MANG), the most appropriate classification is the general regulatory announcement/press release category, which is RNS (Regulatory Filings) as per the provided definitions, or potentially a general announcement if RNS is interpreted strictly as mandatory regulatory filings. Given the context of a premium database classifying corporate news, RNS serves as the best fit for non-standard, material corporate announcements that are disseminated via press release.
2022-06-07 English
Inventiva intègre le segment Tech Leaders d’Euronext
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that Inventiva has joined the Euronext Tech Leaders segment. It contains company news, management quotes, and standard forward-looking statements and contact information typical of a public announcement. It is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a specific regulatory filing form. Since it is a general announcement of a corporate event/news that doesn't fit the highly specific categories like DIV, DIRS, or MANG, the most appropriate classification is the general regulatory announcement/press release category, which aligns best with RNS (Regulatory Filings) as a broad category for non-standard announcements, or potentially ER if it were tied to earnings, which it is not. Given the nature of the announcement (joining an index segment), RNS is the best fit as a general regulatory/market communication.
2022-06-07 French
Inventiva annonce la présentation d’un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association
Regulatory Filings Classification · 98% confidence The document is titled 'Inventiva annonce la présentation d'un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association' and details the selection of a scientific abstract for a poster presentation at a medical conference. It is a press release format ('COMMUNIQUE DE PRESSE') announcing scientific data presentation, not a full financial report (like 10-K or IR) or a general regulatory filing (RNS). Since the content is focused on scientific data presentation and abstracts, it is most closely related to Investor Presentations (IP) which often include scientific updates, or potentially a Regulatory Filing (RNS) if no better fit exists. However, given the specific nature of announcing scientific findings/abstracts for investor/public awareness, 'Investor Presentation' (IP) is a plausible category, although this is a press release *about* a presentation, not the presentation itself. Since it is a press release announcing scientific data/abstract selection, and not a formal financial report, the best fit among the provided options that covers non-financial, non-management, non-legal, non-dividend announcements is often the general 'Regulatory Filings' (RNS) or 'Investor Presentation' (IP). Given the focus on scientific data dissemination, which is a key component of investor relations materials, IP is a strong candidate, but RNS serves as the general announcement/press release fallback. Since this is a press release announcing a scientific abstract presentation, and not a formal presentation document (IP), RNS (Regulatory Filings/General Announcement) is the most appropriate general classification for this type of corporate communication that isn't a core financial filing or specific event announcement.
2022-06-03 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.